Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | |||||||||||||
Title | Abecma (idecabtagene vicleucel) FDA Drug Label | ||||||||||||
|
|||||||||||||
URL | https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Idecabtagene Vicleucel | Idecabtagene Vicleucel | 0 | 4 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Idecabtagene Vicleucel | Abecma | Ide-cel|bb2121|BMS-986395 | Abecma (idecabtagene vicleucel) is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (PMID: 32707894, PMID: 33626253). Abecma (idecabtagene vicleucel) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|